Tag - Neuraly

D&D Pharmatech’s US unit to work with NIH, Johns Hopkins for Parkinson’s research

Neuraly, a U.S. subsidiary of D&D Pharmatech, has announced a collaboration with the National Institute on Aging (NIA) under the National Institutes of Health (NIH) and Johns Hopkins University School of Medicine to advance biomarker research using serum samples from patients involved in the phase 2 clinical trial of NLY01, a treatment for Parkinson's disease. NLY01, a long-acting GLP-1 receptor agonist, is being developed as a therapeutic for neurodegenerative diseases, including Parkinson's disease. he drug recently completed a global phase...
Read more...

Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease

Neuraly, a clinical-stage biotechnology company pioneering development of disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD). The primary endpoint, change from baseline to Week 36 in the sum of MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Examination) after 36 weeks of NLY01 treatment, compared to placebo, did not reach statistical significance. NLY01 was safe and well tolerated. The effect was...
Read more...

Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD). NLY01, Neuraly’s lead development asset, is a glucagon-like peptide 1 receptor (GLP-1R) agonist that has been demonstrated to inhibit pathological activation of microglia by binding upregulated GLP-1R in animal models of neurodegenerative diseases such as PD. Read more >>
Read more...

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Neuraly's investigational therapy NLY01 in people with Alzheimer's disease. The randomized, double-blinded, placebo-controlled trial is expected to enroll more than 500 people with mild cognitive impairment due to Alzheimer’s disease at more than 100 sites in the U.S., Canada, and Europe. Read more >>
Read more...

Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma

Neuraly, Inc, a clinical-stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced a strategic sponsored research agreement with the University of Pennsylvania to study the use of NLY01 to therapeutically target a neuroinflammatory mechanism of glaucoma. Read more >>
Read more...

Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease

Neuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease. NLY01 is also being evaluated in patients with Parkinson’s disease in a Phase 2 trial initiated in February 2020. Read more >>
Read more...

CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease

All mentions of NLY01 have been corrected -- Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease. Read more >>
Read more...